“Bimekizumab Efficacy and Safety through Two Years in Patients With Moderate Psoriasis: Analysis of Pooled Data from Five Phase 3 3b Clinical Trials”. 2022. SKIN The Journal of Cutaneous Medicine 6 (6): s67. https://doi.org/10.25251/skin.6.supp.67.